Roche and Exiqon have agreed to jointly market Roche Applied Science's RealTime ready custom quantitative PCR assays with Exiqon's miRcury LNA Universal RT microRNA qPCR system, the companies said this week.
The co-marketing agreement builds on a licensing agreement related to the same technologies that has been in place since at least 2005, when Roche licensed Exiqon's locked nucleic acid technology to manufacture qPCR assays based on its universal probe library.